Last mentioned: Mar 15, 2026
Eventide Asset Management LLC has reduced its position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant remaining stake valued at $83.65 million. This institutional shift comes as Collegium continues to integrate recent acquisitions and navigate the complex regulatory landscape of the specialty pain management market.
Eventide Asset Management LLC has reduced its position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant $83.65 million stake. This institutional rebalancing occurs as the specialty pharmaceutical sector faces evolving regulatory scrutiny and a transition toward non-opioid pain management solutions.
Collegium Pharmaceutical's Q4 2025 results showcase a successful strategic shift toward diversification, led by the ADHD treatment Jornay PM. Simultaneously, CRA International’s earnings highlight a surging demand for specialized life sciences consulting amid a complex regulatory landscape.